Full Press Release Details
Welcome everybody to Wall Street Reporters. Next super stock live stream
where we bring those stocks, which have that 10 x to 100 x upside potential companies going after massive multi-billion dollar market
opportunities that are at a key inflection point with multiple catalysts in place. And, uh, that brings us to Aditxt, ADTX on Nasdaq and,
uh, the CEO Amro Albanna. Amro, welcome to the program.
Amro Albanna (00:29):
Thank you, Jack. Appreciate all you're doing. Thank you.
Uh, Amro, so, look, I mean, I think the introduction kind of, uh, epitomizes,
uh, Aditxt, I mean, you know, and also deep value right now, which I want to get into again, the stock is trading at, you know, valuation
of, you know, $5 million market cap right now. Uh, and you know, based on everything you have the, you know, the, the assets, which, you
know, we wanna get into the catalyst. I think it's a very exciting time for investors. I, this is really the inflection point, or as we
call, you know, the stock is in the, uh, 10 bagger window. You know, you got all, everything lined up, uh, and, uh, so that's, we just
need you to, you know, hit it out of the park now. So, with that said, for anybody new here, we've got a lot of new people watching. Can
you tell us what is, you know, what's kind of the business model of Aditxt? What do you do in the healthcare space?
Amro Albanna (01:23):
We accelerate promising innovation, Jack, that's as simple as that. We
are publicly owned innovation accelerator company. Uh, reality is there are innovations out there that hold the promise of addressing
some of our most pressing health challenges, autoimmunity, cancer, women's health, you name it. And those innovations typically do not
get the opportunity to be commercialized. So we founded Aditxt as a publicly owned company to advance some of these promising, some of,
some of these most promising innovations, again, that could address autoimmunity or cancer. That's, that's what Aditxt is all about.
Okay. And what, so you have a couple of different, um, you know, subsidiaries,
you, you, you have an acquisition coming up. Tell us about the different, you know, the, the different assets that are inside of the company
Amro Albanna (02:14):
So we currently have two subsidiaries, uh, Adimune, which is going after
autoimmunity. And we have Pearsanta, which is going after early disease detection, starting with prostate cancer, or cancer in general,
but starting with prostate cancer and endometriosis. Those are the two existing subsidiaries right now. And we'll talk a little bit more
in details. And then we, we have a pending acquisition, Evofem. Evofem is also a publicly traded company, uh, focused on women's health.
Uh, they are revenue generating, uh, they reported almost $20 million last year. Evofem is truly an excellent example of our business
model and how, how critical it is for companies like Evofem. Evofem holds tremendous opportunity, we believe, just like our other companies.
And making it part of Aditxt is key for them, realizing their true potential and true opportunities. And again, we'll talk about each
company in more detail. So these are the two that we currently have, and Evofem with a target closing by end of September.
Okay. So that's very interesting. So, uh, Pearsanta and Adimune, those
are still early stage. There's, there are, those are just, uh, I guess, you know, they're, they're going, you know, you're advancing them
towards commercialization, but we, and we'll kind of talk about where they are, but with Evofem, you are act, you know, once that deal
closes, you are actually gonna be a revenue generating company. Aditxt will be a revenue generating company. So they're doing, uh, roughly
we're, we're saying $20 million in revenues. So look, one of the comp in the space, and again, women's health space, like, uh, in, in,
in healthcare companies, what are, what, what, what are the multiples, uh, for revenues typically?
Amro Albanna (03:54):
Right. And, you know, again, I just, I mean, obviously I always have to
mention this, there are certain conditions that we have to meet to be able to close it, including share shareholder approval. Their shareholders
have to approve the transactions, senior notes on and so forth. And that's all reported publicly. But, you know, when you look at comms,
I think when you start looking at women's health in general, this is an area that truly has seen, you know, really not much attention
when it comes to innovations. And Evofem is well positioned to begin addressing. Um, you know, this field starting with non-hormonal birth
control. It's an FDA approved product, and in fact, they also acquired another FDA approved product, Solosec, with our support last year.
So when you talk about comp, I mean, it really depends whether you're looking at it based on revenue, multiple revenues, whether you're
looking at it as multiple of EBITDA, or whether you're looking at it as a growth comp of what potentially Evofem can be.
So without providing guidance on Evofem or any projections, look, $20 million
is what they reported end of 2024, 19 million and change, where we see Evofem going, expanding their product portfolio, which is definitely
something we're, we're looking at. And we've shown that we expanded or supported them expanding their product portfolio with Solosec and
expanding their market share in the US and abroad. And in fact, they also just announced a, another relationship to, to begin expanding
outside the us. So whether you're looking at comps from revenue, EBITDA, or potential, Jack, uh, still, um, it's, it's, it's a great opportunity
that can be realized, we believe.
Okay. But like, you know, so we're talking about basically what, five times
the revenues, 10 times, you know, 10 x, uh, revenues, multiples. What are the comp? I think there are somewhere in the five, between five
Amro Albanna (05:48):
It, it can be, it certainly can be. I mean, again, you know, without providing
any guidance on what the value could be. I mean, look, um, if it's a growth story, then you're gonna start seeing multiples to be higher
because there is a lot of room for growth. Um, okay. You know, with product portfolio, expanding their product portfolio and expanding
their markets, then I believe that your multiples will be higher because it's gonna be based on growth, not, [inaudiable] growth. That's
Okay. So, so you have, so you have a plan to basically to scale up their
business, you know, because it's kind of like a platform, right? It's kind of like a platform company where you can have other, other,
uh, products in there, et cetera.
Amro Albanna (06:30):
Exactly. Whether you're talking about, uh, retail outlets that they have,
whether, you know KOLs, whether it's, um, uh, physician network that takes quite a bit of time and investment to have a platform like
Evofem. Not to mention really starting with a team that, that is committed and understands women women's health. So Saundra and her team,
Saundra, as being the CEO, she understands that field. And that's really what we look for in, in, in Aditxt is a team and leadership that
understands the market. And with our support, they can grow in that market. But just on Evofem, which again, I know we'll talk about Pearsanta
and Adimune here. Um, you know, with, with Evofem, assuming we close the transaction, Jack, now Aditxt goes from transitions from speculative
stage company, like many, many micro cap companies to a company that can show real fundamentals in terms of income statement, balance
sheet. And that's where we're pushing Aditxt towards fundamentals, um, beyond speculative stage. And that's key for us.
Yeah, absolutely. Uh, I mean, that, that's, uh, that's where the inflection
point happens. Now, what about, uh, let's talk about, uh, tell us a little bit more, maybe if we can get into some details about Adimune
and Pearsanta. What it drill down to some of the details? What are the, what do those, uh, operation, uh, subsidiaries do?
Amro Albanna (07:52):
Sure. So let me take it in this order, because, you know, with, with Evofem,
you know, if we close the transaction, that becomes the first, you know, revenue generating under Aditxt, right? And we discussed what
they reported last year. So let's begin with Pearsanta, because Pearsanta is near commercialization. And the whole concept of Pearsanta,
and the reason we actually did the acquisition, the asset acquisition, couple of them that we did last year, um, is the fact that we believe
the best way to address a disease has to begin with early detection. I mean, let's take cancer. I think all your viewers right now, uh,
you know, they agree with the fact that the earlier you detect cancer, the better. I think that's a fact that we all agree and, and the
word cancer, nobody wants to hear. So imagine if we have the ability to early detect cancer with more precision.
So with our acquisition of the Mitomic platform, which basically uses mitochondrial
DNA to detect cancer, um, we're positioning Pearsanta where we can, where we can bring this platform to commercialization as early as
end of the year or Q1 of 2026. The key is to have existing infrastructure. And that's really important for your audience to understand
that we're not talking about ideas, we're not talking about just, you know, inspiration. Pearsanta has an existing infrastructure, including
CLIA-CAP monitoring center laboratory, in Richmond, Virginia, with, with qualified staff that's pushing towards validation, validating
the assay that, that basically the test. So our goal is by end of this year or Q1 of next year, for Pearsanta to transition to commercialization,
yet another inflection point for Aditxt that it's in the near term, relatively speaking.
So what they need, uh, what's what, so what's the path from where, where
we are now to get to that, uh, you know, FDA clearance? What's the, what, what, what's, what are the milestones between now and, you know,
and, and, you know, next, next six months, let's call it?
Amro Albanna (10:03):
Right? So regulatory approval, I'm glad you asked that question. It's not
really an FDA, uh, process. It's a CLIA-CAP, which is required by laboratories where the test is not being conducted by the consumer.
It's actually being processed inside our lab. So you have very rigorous regulations like CLIA and CAP, including the staff, uh, the team,
the infrastructure, the way we validate the tests, and that's in place, and that's what the team is doing right now to validate those
to go commercial by end of the year or Q1. Once you go commercial, we start, obviously, you know, once we're ready, we start engaging
with distributors to be able to bring those tests, uh, to the, you know, commercially in the US, Europe, and beyond. So Pearsanta is near
Okay. So this, okay, so the, there is no, so there, there is, you don't
need FDA approval for this. You're basically, you're right. It to go, uh, what and which, what kind of cancers, what's, and what, what,